Viatris Fined $1.9 Million Over Alleged Violation of Antitrust Restrictions

MT Newswires Live11-22 22:02

Viatris (VTRS) has been fined 1.5 million UK pounds ($1.9 million) by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff changes and failing to report the breach, the regulator said Friday.

The penalty was imposed in response to Viatris' sale of the European right to its hormone replacement therapy treatments Duphaston and Femoston to Theramex, which the regulator said could reduce competition.

The regulator said Viatris breached restrictions imposed on it during an investigation by "implementing changes to key members of its UK management team" without consent and failing to notify authorities of the breach.

Viatris did not immediately reply to MT Newswires' request for comment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485265037?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485265037","market":"us","top_or_hot":-1,"title":"Viatris Fined $1.9 Million Over Alleged Violation of Antitrust Restrictions","media":"MT Newswires Live","content":"<html><body><p> Viatris (VTRS) has been fined 1.5 million UK pounds ($1.9 million) by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff changes and failing to report the breach, the regulator said Friday.</p><p>The penalty was imposed in response to Viatris' sale of the European right to its hormone replacement therapy treatments Duphaston and Femoston to Theramex, which the regulator said could reduce competition.</p><p>The regulator said Viatris breached restrictions imposed on it during an investigation by \"implementing changes to key members of its UK management team\" without consent and failing to notify authorities of the breach.</p><p>Viatris did not immediately reply to MT Newswires' request for comment.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viatris Fined $1.9 Million Over Alleged Violation of Antitrust Restrictions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViatris Fined $1.9 Million Over Alleged Violation of Antitrust Restrictions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viatris (VTRS) has been fined 1.5 million UK pounds ($1.9 million) by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485265037","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485265037","pubTimestamp":1732284138,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Viatris  has been fined 1.5 million UK pounds  by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff changes and failing to report the breach, the regulator said Friday.The penalty was imposed in response to Viatris' sale of the European right to its hormone replacement therapy treatments Duphaston and Femoston to Theramex, which the regulator said could reduce competition.The regulator said Viatris breached restrictions imposed on it during an investigation by \"implementing changes to key members of its UK management team\" without consent and failing to notify authorities of the breach.Viatris did not immediately reply to MT Newswires' request for comment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","VTRS":"Viatris Inc.","BK4588":"碎股","BK4583":"猴痘概念","BK4007":"制药","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC"},"translate_title":"Viatris因涉嫌违反反垄断限制被罚款190万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9},"content_text":"Viatris (VTRS) has been fined 1.5 million UK pounds ($1.9 million) by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff changes and failing to report the breach, the regulator said Friday.The penalty was imposed in response to Viatris' sale of the European right to its hormone replacement therapy treatments Duphaston and Femoston to Theramex, which the regulator said could reduce competition.The regulator said Viatris breached restrictions imposed on it during an investigation by \"implementing changes to key members of its UK management team\" without consent and failing to notify authorities of the breach.Viatris did not immediately reply to MT Newswires' request for comment.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485265037"}